Article navigation

Introduction: Transition zone PSA density (TZ-PSAD) was proposed to improve prostate cancer detection by normalizing PSA to the compartment most affected by benign prostatic hyperplasia (BPH). If valid, TZ-PSAD should provide the greatest benefit in large prostates where BPH predominates. We tested this assumption across prostate volume categories in the largest MRI-based cohort reported to date. Materials and Methods: We analyzed 3,958 consecutive patients who underwent multiparametric MRI with manual zonal segmentation and combined MRI-guided targeted plus systematic transperineal biopsy (March 2010–June 2025). Diagnostic accuracy of TZ-PSAD versus whole-gland PSAD was compared using receiver operating characteristic analysis with DeLong testing. Volume-stratified subgroup analysis (<30 mL, 30–50 mL, and >50 mL) assessed performance consistency. Clinical utility was evaluated by decision curve analysis (DCA). Results: Of 3,958 patients, 1,629 (41.2%) had clinically significant prostate cancer (International Society of Urological Pathology grade group: ≥2). TZ-PSAD achieved marginally superior area under the curve (AUC) (0.768 vs. 0.758, p < 0.001; ΔAUC 0.010). Volume-stratified analysis revealed inconsistent performance: TZ-PSAD was inferior in small prostates (<30 mL: ΔAUC −0.017, p = 0.015), modestly beneficial at intermediate volumes (30–50 mL: ΔAUC +0.013, p = 0.026), and nonsignificant in large glands (>50 mL: ΔAUC +0.006, p = 0.462). DCA confirmed fewer than 1 additional cancer detected per 1,000 patients at clinically relevant thresholds. Limitations include the retrospective single-center design, absence of PI-RADS-stratified analysis, and incomplete capture of 5-alpha reductase inhibitor exposure. Conclusion: TZ-PSAD fails to outperform whole-gland PSAD in prostates >50 mL, where its theoretical rationale is strongest. The additional complexity of zonal segmentation is not justified for routine clinical use.

1.
Benson
MC
,
Whang
IS
,
Olsson
CA
,
McMahon
DJ
,
Cooner
WH
.
The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
.
J Urol
.
1992
;
147
(
3 Pt 2
):
817
21
.
2.
Wang
S
,
Kozarek
J
,
Russell
R
,
Drescher
M
,
Khan
A
,
Kundra
V
, et al
.
Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic review and meta-analysis
.
Eur Urol Oncol
.
2024
;
7
(
2
):
189
203
.
3.
Feng
ZJ
,
Xue
C
,
Wen
JM
,
Li
Y
,
Wang
M
,
Zhang
N
, et al
.
PSAD test in the diagnosis of prostate cancer: a meta-analysis
.
Clin Lab
.
2017
;
63
(
1
):
147
55
.
4.
Van Poppel
H
,
Roobol
MJ
,
Chapple
CR
,
Catto
JWF
,
N’Dow
J
,
Sønksen
J
, et al
.
Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021
.
Eur Urol
.
2021
;
80
(
6
):
703
11
.
5.
Kalish
J
,
Cooner
WH
,
Graham
SD
.
Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate
.
Urology
.
1994
;
43
(
5
):
601
6
.
6.
Zlotta
AR
,
Djavan
B
,
Marberger
M
,
Schulman
CC
.
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction
.
J Urol
.
1997
;
157
(
4
):
1315
21
.
7.
Djavan
B
,
Zlotta
AR
,
Byttebier
G
,
Shariat
S
,
Omar
M
,
Schulman
CC
, et al
.
Prostate specific antigen density of the transition zone for early detection of prostate cancer
.
J Urol
.
1998
;
160
(
2
):
411
9
; discussion 418–419.
8.
Pausch
AM
,
Ghafoor
S
,
Notter
R
,
Benke-Bruderer
S
,
von Felten
S
,
Rupp
NJ
, et al
.
MRI-based risk stratification for clinically significant prostate cancer detection at biopsy: the value of zonal-specific PSA density and PSHS
.
Eur J Radiol
.
2025
;
184
:
111982
.
9.
Kuanar
S
,
Cai
J
,
Nakai
H
,
Nagayama
H
,
Takahashi
H
,
LeGout
J
, et al
.
Transition-zone PSA-density calculated from MRI deep learning prostate zonal segmentation model for prediction of clinically significant prostate cancer
.
Abdom Radiol
.
2024
;
49
(
10
):
3722
34
.
10.
Chang
TH
,
Lin
WR
,
Tsai
WK
,
Chiang
PK
,
Chen
M
,
Tseng
JS
, et al
.
Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in taiwanese males with PSA < 20 ng/ml
.
BMC Urol
.
2020
;
20
(
1
):
151
.
11.
Esengur
OT
,
Stevenson
E
,
Stecko
H
,
Lay
NS
,
Yang
D
,
Tetreault
J
, et al
.
Assessing the impact of transition and peripheral zone PSA densities over whole-gland PSA density for prostate cancer detection on multiparametric MRI
.
Prostate
.
2025
;
85
(
6
):
612
24
.
12.
Jin
Y
,
Chen
F
,
Xu
G
,
Wei
C
,
Dong
C
.
Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions
.
Sci Rep
.
2025
;
15
(
1
):
3258
.
13.
Nordström
T
,
Akre
O
,
Aly
M
,
Grönberg
H
,
Eklund
M
.
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
.
Prostate Cancer Prostatic Dis
.
2018
;
21
(
1
):
57
63
.
14.
Aminsharifi
A
,
Howard
L
,
Wu
Y
,
De Hoedt
A
,
Bailey
C
,
Freedland
SJ
, et al
.
Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index
.
J Urol
.
2018
;
200
(
4
):
758
66
.
15.
Quarta
L
,
Pellegrino
F
,
Stabile
A
,
Scilipoti
P
,
Longoni
M
,
Cannoletta
D
, et al
.
Does the accuracy of prostate-specific antigen density in identifying clinically significant prostate cancer change with prostate volume?
.
Eur Urol Focus
.
2025
;
S2405-4569
(
25
).
16.
Durmaz
S
,
Wu
SCJ
,
Lee
KL
,
Shakur
A
,
Caglic
I
,
Barrett
T
, et al
.
The effects of prostate volume and PI-RADS category on optimal PSA-density thresholds for biopsy decision-making
.
Eur Radiol
.
2026
;
36
(
6
):
4503
12
.
17.
Omri
N
,
Kamil
M
,
Alexander
K
,
Alexander
K
,
Edmond
S
,
Ariel
Z
, et al
.
Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume
.
Prostate
.
2020
;
80
(
16
):
1444
9
.
18.
Weinreb
JC
,
Barentsz
JO
,
Choyke
PL
,
Cornud
F
,
Haider
MA
,
Macura
KJ
, et al
.
PI-RADS prostate imaging: reporting and data system – 2015, version 2
.
Eur Urol
.
2016
;
69
(
1
):
16
40
.
19.
Turkbey
B
,
Rosenkrantz
AB
,
Haider
MA
,
Padhani
AR
,
Villeirs
G
,
Macura
KJ
, et al
.
Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2
.
Eur Urol
.
2019
;
76
(
3
):
340
51
.
20.
Fedorov
A
,
Beichel
R
,
Kalpathy-Cramer
J
,
Finet
J
,
Fillion-Robin
JC
,
Pujol
S
, et al
.
3D Slicer as an image computing platform for the quantitative imaging network
.
Magn Reson Imaging
.
2012
;
30
(
9
):
1323
41
.
21.
Epstein
JI
,
Egevad
L
,
Amin
MB
,
Delahunt
B
,
Srigley
JR
,
Humphrey
PA
, et al
.
The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system
.
Am J Surg Pathol
.
2016
;
40
(
2
):
244
52
.
22.
Cornford
P
,
Van Den Bergh
RCN
,
Briers
E
,
Van Den Broeck
T
,
Brunckhorst
O
,
Darraugh
J
, et al
.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer: 2024 update. Part I – screening, diagnosis, and local treatment with curative intent
.
Eur Urol
.
2024
;
86
(
2
):
148
63
.
23.
Hu
JC
,
Assel
M
,
Allaf
ME
,
Vickers
AJ
,
Ehdaie
B
,
Cohen
AJ
, et al
.
Transperineal vs transrectal prostate biopsy-the PREVENT randomized clinical trial
.
JAMA Oncol
.
2024
;
10
(
11
):
1590
.
24.
Hanley
JA
,
McNeil
BJ
.
The meaning and use of the area under a receiver operating characteristic (ROC) curve
.
Radiology
.
1982
;
143
(
1
):
29
36
.
25.
DeLong
ER
,
DeLong
DM
,
Clarke-Pearson
DL
.
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
.
Biometrics
.
1988
;
44
(
3
):
837
45
.
26.
Vickers
AJ
,
Elkin
EB
.
Decision curve analysis: a novel method for evaluating prediction models
.
Med Decis Making
.
2006
;
26
(
6
):
565
74
.
27.
Distler
FA
,
Radtke
JP
,
Bonekamp
D
,
Kesch
C
,
Schlemmer
HP
,
Wieczorek
K
, et al
.
The value of PSA density in combination with PI-RADSTM for the accuracy of prostate cancer prediction
.
J Urol
.
2017
;
198
(
3
):
575
82
.
28.
Jue
JS
,
Barboza
MP
,
Prakash
NS
,
Venkatramani
V
,
Sinha
VR
,
Pavan
N
, et al
.
Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy
.
Urology
.
2017
;
105
:
123
8
.
29.
Robinson
E
,
Kinsella
N
,
Ap Dafydd
D
,
Shur
J
,
Sohaib
A
,
Hazell
S
, et al
.
Prostate specific antigen density and clinically-significant prostate cancer: the influence of prostatic volume
.
Prostate
.
2025
;
85
(
8
):
784
91
.
30.
Elliott
CS
,
Shinghal
R
,
Presti
JC
.
The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes
.
J Urol
.
2008
;
179
(
5
):
1756
61
; discussion 1761.
31.
Hamzaoui
D
,
Montagne
S
,
Granger
B
,
Allera
A
,
Ezziane
M
,
Luzurier
A
, et al
.
Prostate volume prediction on MRI: tools, accuracy and variability
.
Eur Radiol
.
2022
;
32
(
7
):
4931
41
.
32.
Salvaggio
G
,
Comelli
A
,
Portoghese
M
,
Cutaia
G
,
Cannella
R
,
Vernuccio
F
, et al
.
Deep learning network for segmentation of the prostate gland with median lobe enlargement in T2-weighted MR images: Comparison with manual segmentation method
.
Curr Probl Diagn Radiol
.
2022
;
51
(
3
):
328
33
.
33.
Marks
LS
,
Andriole
GL
,
Fitzpatrick
JM
,
Schulman
CC
,
Roehrborn
CG
.
The interpretation of serum prostate specific antigen in men receiving 5α-Reductase inhibitors: a review and clinical recommendations
.
J Urol
.
2006
;
176
(
3
):
868
74
.
34.
Falagario
UG
,
Lantz
A
,
Jambor
I
,
Busetto
GM
,
Bettocchi
C
,
Finati
M
, et al
.
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
.
World J Urol
.
2023
;
41
(
11
):
2967
74
.
35.
Pagniez
MA
,
Kasivisvanathan
V
,
Puech
P
,
Drumez
E
,
Villers
A
,
Olivier
J
, et al
.
Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis
.
J Urol
.
2020
;
204
(
1
):
24
32
.
36.
Schoots
IG
,
Roobol
MJ
.
Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
.
World J Urol
.
2020
;
38
(
3
):
517
29
.
You do not currently have access to this content.
Don't already have an account? Register

Digital Version

Pay-Per-View Access
$45.00
Rental

or Create an Account

Close Modal
Close Modal